Using the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments

Aneeta Saxena; Sara Paredes-Echeverri; Rosa Michaelis; Stoyan Popkirov; David L. Perez

doi:10.1055/s-0041-1742145

Seminars in Neurology, Table of Contents

Semin Neurol 2022; 42(02): 080-087
DOI: 10.1055/s-0041-1742145

Review Article

Using the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments

Aneeta Saxena ‡^*

¹Epilepsy Division, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts

²Functional Neurological Disorder Unit, Division of Cognitive Behavioral Neurology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

,

Sara Paredes-Echeverri ‡^*

²Functional Neurological Disorder Unit, Division of Cognitive Behavioral Neurology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

,

Rosa Michaelis

³Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany

⁴Department of Neurology, Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany

,

Stoyan Popkirov

³Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany

,

David L. Perez

²Functional Neurological Disorder Unit, Division of Cognitive Behavioral Neurology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

⁵Division of Neuropsychiatry, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

› Author Affiliations

Abstract

The biopsychosocial model was defined by George L. Engel to propose a holistic approach to patient care. Through this model, physicians can understand patients in their context to aid the development of tailored, individualized treatment plans that consider relevant biological, psychological, and social–cultural–spiritual factors impacting health and longitudinal care. In this article, we advocate for the use of the biopsychosocial model in neurology practice across outpatient and inpatient clinical settings. To do so, we first present the history of the biopsychosocial model, and its relationships to precision medicine and deep phenotyping. Then, we bring the neurologist up-to-date information on the components of the biopsychosocial clinical formulation, including predisposing, precipitating, perpetuating, and protective factors. We conclude by detailing illustrative neurological case examples using the biopsychosocial model, emphasizing the importance of considering relevant psychological and social factors to aid the delivery of patient-centered clinical care in neurology.

Keywords

biopsychosocial - neurology - education - behavioral neurology - neuropsychiatry

Full Text

References

References
1 Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196 (4286): 129-136
2 Engel GL. The need for a new medical model: a challenge for biomedicine. Psychodyn Psychiatry 2012; 40 (03) 377-396
3 Sadler JZ, Hulgus YF. Knowing, valuing, acting: clues to revising the biopsychosocial model. Compr Psychiatry 1990; 31 (03) 185-195
4 Grinker Sr RR. A struggle for eclecticism. Am J Psychiatry 1964; 121: 451-457
5 Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry 1980; 137 (05) 535-544
6 Adler RH. Engel's biopsychosocial model is still relevant today. J Psychosom Res 2009; 67 (06) 607-611
7 Wade DT, Halligan PW. The biopsychosocial model of illness: a model whose time has come. Clin Rehabil 2017; 31 (08) 995-1004
8 Asadi-Pooya AA, Brigo F, Kozlowska K. et al. Social aspects of life in patients with functional seizures: closing the gap in the biopsychosocial formulation. Epilepsy Behav 2021; 117: 107903
9 Dhand A, Luke DA, Lang CE, Lee JM. Social networks and neurological illness. Nat Rev Neurol 2016; 12 (10) 605-612
10 Perez DL, Keshavan MS, Scharf JM, Boes AD, Price BH. Bridging the great divide: What can neurology learn from psychiatry?. J Neuropsychiatry Clin Neurosci 2018; 30 (04) 271-278
11 Keshavan MS, Price BH, Martin JB. The convergence of neurology and psychiatry: the importance of cross-disciplinary education. JAMA 2020; 324 (06) 554-555
12 Martin JB. The integration of neurology, psychiatry, and neuroscience in the 21st century. Am J Psychiatry 2002; 159 (05) 695-704
13 Parimbelli E, Marini S, Sacchi L, Bellazzi R. Patient similarity for precision medicine: a systematic review. J Biomed Inform 2018; 83: 87-96
14 Bird TD. Thoughts on the relationship of the human genome project to neurology. Arch Neurol 2001; 58 (11) 1764-1765
15 Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Adv Exp Med Biol 2019; 1168: 9-30
16 Paré PD. Genetic testing for respiratory disease: are we there yet?. Can Respir J 2012; 19 (04) 246-248
17 Kline EM, Houser MC, Herrick MK. et al. Genetic and environmental factors in Parkinson's disease converge on immune function and inflammation. Mov Disord 2021; 36 (01) 25-36
18 Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol 2019; 26 (01) 27-40
19 Waung MW, Taylor A, Qualmann KJ, Burish MJ. Family history of cluster headache: a systematic review. JAMA Neurol 2020; 77 (07) 887-896
20 Ashley EA. The precision medicine initiative: a new national effort. JAMA 2015; 313 (21) 2119-2120
21 Hawgood S, Hook-Barnard IG, O'Brien TC, Yamamoto KR. Precision medicine: beyond the inflection point. Sci Transl Med 2015; 7 (300) 300ps17
22 EpiPM Consortium. A roadmap for precision medicine in the epilepsies. Lancet Neurol 2015; 14 (12) 1219-1228
23 Kearney H, Byrne S, Cavalleri GL, Delanty N. Tackling epilepsy with high-definition precision medicine: a review. JAMA Neurol 2019; 76 (09) 1109-1116
24 Chitnis T, Prat A. A roadmap to precision medicine for multiple sclerosis. Mult Scler 2020; 26 (05) 522-532
25 Delude CM. Deep phenotyping: the details of disease. Nature 2015; 527 (7576): S14-S15
26 Gibbs RM, Lipnick S, Bateman JW. et al. Toward precision medicine for neurological and neuropsychiatric disorders. Cell Stem Cell 2018; 23 (01) 21-24
27 Robinson PN. Deep phenotyping for precision medicine. Hum Mutat 2012; 33 (05) 777-780
28 Dorsey ER, Omberg L, Waddell E. et al. Deep phenotyping of Parkinson's disease. J Parkinsons Dis 2020; 10 (03) 855-873
29 Isaacson RS, Ganzer CA, Hristov H. et al. The clinical practice of risk reduction for Alzheimer's disease: a precision medicine approach. Alzheimers Dement 2018; 14 (12) 1663-1673
30 Krivanek TJ, Gale SA, McFeeley BM, Nicastri CM, Daffner KR. Promoting successful cognitive aging: a ten-year update. J Alzheimers Dis 2021; 81 (03) 871-920
31 Winters NC, Hanson G, Stoyanova V. The case formulation in child and adolescent psychiatry. Child Adolesc Psychiatr Clin N Am 2007; 16 (01) 111-132 , ix
32 Yang Z, Wu H, Lee PH. et al. Investigating shared genetic basis across Tourette syndrome and comorbid neurodevelopmental disorders along the impulsivity-compulsivity spectrum. Biol Psychiatry 2021; 90 (05) 317-327
33 Fisher CM. Transient global amnesia. Precipitating activities and other observations. Arch Neurol 1982; 39 (10) 605-608
34 Szaflarski M, Wolfe JD, Tobias JGS, Mohamed I, Szaflarski JP. Poverty, insurance, and region as predictors of epilepsy treatment among US adults. Epilepsy Behav 2020; 107: 107050
35 Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol 2018; 14 (11) 653-666
36 Josephson CB, Engbers JDT, Jette N. et al. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurol 2019; 76 (04) 440-446
37 Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry 2007; 68 (07) 1010-1013
38 Scott BR, Uomoto JM, Barry ES. Impact of pre-existing migraine and other co-morbid or co-occurring conditions on presentation and clinical course following deployment-related concussion. Headache 2020; 60 (03) 526-541
39 Chen CL, Lin MY, Huda MH, Tsai PS. Effects of cognitive behavioral therapy for adults with post-concussion syndrome: a systematic review and meta-analysis of randomized controlled trials. J Psychosom Res 2020; 136: 110190
40 Kaufmann AM, Price AV. A history of the Jannetta procedure. J Neurosurg 2019; 132 (02) 639-646
41 Frucht L, Perez DL, Callahan J. et al. Functional dystonia: differentiation from primary dystonia and multidisciplinary treatments. Front Neurol 2021; 11: 605262
42 Baslet G, Bajestan SN, Aybek S. et al. Evidence-based practice for the clinical assessment of psychogenic nonepileptic seizures: a report from the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2021; 33 (01) 27-42
43 Espay AJ, Aybek S, Carson A. et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 2018; 75 (09) 1132-1141
44 Perez DL, Aybek S, Popkirov S. et al; (On behalf of the American Neuropsychiatric Association Committee for Research. A review and expert opinion on the neuropsychiatric assessment of motor functional neurological disorders. J Neuropsychiatry Clin Neurosci 2021; 33 (01) 14-26